DrugPatentWatch Database Preview

Drugs in Development Information for Fotemustine

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Fotemustine?

Fotemustine is an investigational drug.

There have been 17 clinical trials for Fotemustine. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1^st 2012.

The most common disease conditions in clinical trials are Melanoma, Uveal Neoplasms, and Lymphoma. The leading clinical trial sponsors are Bristol-Myers Squibb, Mingzhi Zhang, and Hoffmann-La Roche.

There is one US patent protecting this investigational drug and twenty-four international patents.

Summary for Fotemustine

US Patents	1,817
International Patents	24,495
US Patent Applications	4,821
WIPO Patent Applications	0
Japanese Patent Applications	2,387
Clinical Trial Progress	Phase 3 (2012-06-01)
Vendors	67

Recent Clinical Trials for Fotemustine

Title	Sponsor	Phase
A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma	Mingzhi Zhang	Phase 4
Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma	Mingzhi Zhang	Phase 4
A Phase I/IIa Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT	Genenta Science	Phase 1/Phase 2

See all Fotemustine clinical trials

Clinical Trial Summary for Fotemustine

Top disease conditions for Fotemustine

Top clinical trial sponsors for Fotemustine

See all Fotemustine clinical trials

US Patents for Fotemustine

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Fotemustine		Heat shock protein 70 (hsp-70) receptor ligands	Duke University (Durham, NC)
Fotemustine		Compounds and their methods of use	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Fotemustine		Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus	Seattle Genetics, Inc. (Bothell, WA)
Fotemustine		Anti-FGFR3 antibodies and methods using same	Genentech, Inc. (South San Francisco, CA)
Fotemustine		Bispecific antigen-binding constructs targeting HER2	Zymeworks Inc. (Vancouver, CA)
Fotemustine		Method of diagnosing and treating cancer using B-catenin splice variants	The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)

International Patents for Fotemustine

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Fotemustine	World Intellectual Property Organization (WIPO)	WO2015148714	2034-03-25
Fotemustine	Australia	AU2015231053	2034-03-21
Fotemustine	Brazil	BR112016021620	2034-03-21
Fotemustine	Canada	CA2943339	2034-03-21
Fotemustine	China	CN106231900	2034-03-21
Fotemustine	Eurasian Patent Organization	EA201691896	2034-03-21